Home/Pipeline/CYNK-001

CYNK-001

Acute Myeloid Leukemia (AML), Multiple Myeloma

Phase 1Active

Key Facts

Indication
Acute Myeloid Leukemia (AML), Multiple Myeloma
Phase
Phase 1
Status
Active
Company

About Celularity

Celularity is a vertically integrated cell therapy company with a mission to harness the postpartum placenta to create scalable, off-the-shelf cellular medicines. Its achievements include a robust, GMP-capable manufacturing facility, a diverse pipeline of placental-derived cell therapies and biomaterials, and strategic financial moves to bolster its longevity-focused strategy. The company's core strategy is to overcome the traditional barriers of cell therapy—scale, cost, and patient-specific manufacturing—by utilizing a readily available, ethically non-controversial biological source.

View full company profile